Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Boehringer Ingelheim
Baxter
Moodys
McKinsey

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,350,741

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,350,741
Title: Enteric formulations of physiologically active peptides and proteins
Abstract:An enteric formulation for a proteinous drug which protects it from enzymatic degradation and promotes its uptake by the intestinal tract when administered orally, comprises either a solid mass of an intimate mixture of the drug, a nontoxic nonionic surfactant, and an enteric material, or a solid mass of an intimate mixture of the drug with the nonionic surfactant covered by a discrete enteric coating.
Inventor(s): Takada; Kanji (Shimogyo-ku, Kyoto-shi, Kyoto 600, JP)
Assignee:
Application Number:07/888,324
Patent Claims:1. A solid enteric pharmaceutical formulation consisting of a particulate intimate physical mixture of a (a) physiologically active peptide or protein, (b) a nontoxic nonionic surfactant, (c) a pharmaceutically acceptable solid organic acid selected from the group consisting of tartaric, malonic, maleic, malic, citric and cinnamic acids (d), at least 50 wt. %, based on the weight of the pharmaceutical formulation, of a pharmaceutically acceptable, enteric polymer which is soluble in a volatile organic solvent and which dissolves selectively from the mixture in duodenal juice when the mixture is ingested and, optionally, (e) either or both of a pharmaceutically acceptable solid diluent and an effervescing agent.

2. The pharmaceutical formulation of claim 1 wherein the effervescing agent is sodium bicarbonate.

3. The pharmaceutical formulation of claim 1 which contains not less than 80 wt. %, based on the weight of the formulation, of the enteric polymer.

4. The pharmaceutical formulation of claim 1, wherein the peptide or protein is insulin, human granulocyte colony-stimulating factor, a renin inhibitor peptide or cyclosporin A.

5. The pharmaceutical formulation of claim 1, wherein the organic acid is L-tartaric acid.

6. The pharmaceutical formulation of claim 1, wherein the formulation is in granule form.

7. The pharmaceutical formulation of claim 1, in tablet, capsule or other solid unit dosage form.

8. The pharmaceutical formulation according to claim 1, wherein the surfactant is selected from the group consisting of sorbitan fatty acid ester, polyoxyethylene-sorbitan fatty acid ester, polyoxyethylene-hydrogenated castor oil, fatty acid alkanolamide, sucrose fatty acid esters, glycerol mono-, di- and trioctanoate, and the enteric material is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose phthalate, carboxylmethylethylcellulose and methacrylic acid-methyl methacrylate copolymer.

9. The enteric pharmaceutical formulation according to claim 1, in the form of a particulate mixture of the physiologically active peptide or protein and the surfactant, with an enteric coating on the particles of the mixture of the enteric material.

10. The enteric pharmaceutical formulation according to claim 9, wherein the surfactant is selected from the group consisting of sorbitan fatty acid ester, polyoxyethylenesorbitan fatty acid ester, polyoxyethylene-hydrogenated castor oil, fatty acid alkanolamide, sucrose fatty acid esters, glycerol mono-, di- and trioctanoate, and the enteric material is selected from the group consisting of cellulose acetate phthalate, hydroxy propylmethylcellulose succinate, hydroxypropylmethylcellulose phthalate, carboxylmethylethylcellulose and methacrylic acid-methyl methacrylate copolymer.

11. An enteric pharmaceutical formulation according to claim 10, wherein the physiologically active peptide or protein is selected from the group consisting of angiotensin II antagonist peptide, bradykinin, calcitonin-gene associated factor, tissue plasminogen activators, cholecystokinin, delta sleep-inducing peptide (DSIP), .beta.-endorphin, atriopeptin, .alpha.-and .beta.-melanocyte-stimulating hormone, nerve peptide, nerve growth factor (NGF), gastrin antagonist peptide, neurotensin, somatostatin, the colony-stimulating factors G-CSF and GM-CSF, interferon, thymopoietin, tumor necrosis factor, growth hormone, growth hormone-carrier protein complex, human atrial natriuretic peptide (HANP), insulin, luteinizing hormone-releasing factor (LHRH), streptokinase, erythropoietin, urokinase, lysozyme, vasopressin (8- lysine and 8-arginine), oxytocin, desmopressin, cytochrome C, histamine-releasing factor, platelet related growth factor, human chorionic gonadotropin (HCG), human growth hormone (HGH), adrenocorticotropin (ACTH), calcitonin, parathyroid hormone, Factor XIII, Factor IX, MSH release inhibiting factor, enkephalin, thyrotropin releasing hormone, interleukins and renin inhibitor peptides.

12. The pharmaceutical formulation according to claim 11, wherein the surfactant is selected from the group consisting of: sorbitan fatty acid ester, polyoxyethylene-sorbitan fatty acid ester, polyoxyethylene-hydrogenated castor oil, fatty acid alkanolamide, sucrose fatty acid esters, glycerol mono-, di- and trioctanoate, and the enteric material is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose phthalate, carboxylmethylethylcellulose and methacrylic acid-methyl methacrylate copolymer.

13. The pharmaceutical formulation of claim 11, wherein the peptide or protein is insulin, human granulocyte colony-stimulating factor, a renin inhibitor peptide or cyclosporin A.

14. A solid ingestible enteric pharmaceutical formulation consisting of a solid particulate mixture of (a) a physiologically active peptide or protein, (b) a nontoxic nonionic surfactant, (c) a pharmaceutically acceptable solid organic acid selected from the group consisting of tartaric, malonic, maleic, malic, citric and cinnamic acids and, optionally, (d) an inert solid diluent; the particles of which are covered with at least 50 wt. %, based on the weight of the formulation, of a polymer as a discrete enteric coating which covers the surface of the individual particles of the mixture, which coating is soluble in a volatile organic solvent and dissolves selectively in duodenal juice when the mixture is ingested.

15. The pharmaceutical formulation of claim 14, wherein the effervescing agent is sodium bicarbonate.

16. The pharmaceutical formulation of claim 14, which contains not less than 80 wt. %, based on the weight of the formulation, of the enteric polymer.

17. The pharmaceutical formulation of claim 14, wherein the peptide or protein is insulin, human granulocyte colony-stimulating factor, a renin inhibitor peptide or cyclosporin A.

18. The pharmaceutical formulation of claim 14, wherein the organic acid is L-tartaric acid.

19. The pharmaceutical formulation of claim 14, wherein the formulation is in granule form.

20. The pharmaceutical formulation of claim 14, in tablet, capsule or other solid unit dosage form.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan63-191185Jul 30, 1988

Details for Patent 5,350,741

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial 2011-09-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial 2011-09-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial 2011-09-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial 2011-09-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
Mallinckrodt
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.